U.S. Markets open in 6 hrs 21 mins

Aratana sees FDA approval for grapriprant in 2016

Aratana Therapeutics announced findings form the company's ongoing safety and clinical programs, which were presented at the 2014 AVCIM forum. Aratna said it has initiated a pivotal field effectiveness study of grapriprant in client-owned dogs with a once-daily does and continues to anticipate FDA approval in 2016. Aratna also anticipates starting a pilot field study in client-owned cats in 2014.